Show simple item record

dc.contributor.authorValluri, Satish
dc.date.accessioned2012-02-10T17:18:58Z
dc.date.available2012-02-10T17:18:58Z
dc.date.issued2009
dc.identifier.urihttp://hdl.handle.net/10713/851
dc.descriptionUniversity of Maryland in Baltimore. Pharmaceutical Health Services Research. Ph.D. 2009en_US
dc.description.abstractBackground: To investigate the impact of the FDA pediatric antidepressant warning in March 2004 on: 1) the treatment of new-onset depression diagnosis (NODD); 2) physician specialty practice patterns; and 3) the stock returns of the antidepressant manufacturers. Methods: Youth 2-17 years old with a NODD from 2003-2006 constituted the study population. i3 Innovus database containing administrative claims information of U.S. commercial insurance enrollees was used. National Ambulatory Medical Care Survey data (2001-2006) were used to examine antidepressant use by physician specialty during youth mental health visits. CRSP stock price data (2003-2006) was used to examine the warning impact on stock returns and volatility. Results: The warnings led to a statistically significant decrease in the likelihood of antidepressant use [Odds Ratio (OR) =0.83; CI: 0.75,0.92] and an increase in the likelihood of psychotherapy in NODD but not a significant impact on youth with MDD. The likelihood of an antidepressant prescription was significantly higher for psychiatrist visits compared to primary care (OR=3.78; CI: 2.72,5.25). The warning was associated with a non-significant impact on the magnitude of stock returns but a significant increase in the volatility of stock returns (mean change = 0.30; CI: 0.10,0.49). Conclusions: The FDA warning did not lead to a A) decrease in the likelihood of antidepressant use for youth with a diagnosis of major depression, whereas psychotherapy use increased; B) increase the likelihood of antidepressant prescribing by psychiatrists relative to primary care; C) decrease in stock returns but only a modest increase in volatility of stock returns.en_US
dc.language.isoen_USen_US
dc.subject.lcshAntidepressants--Economic aspectsen_US
dc.subject.lcshAntidepressants--Government policyen_US
dc.subject.lcshDepression in children--Treatmenten_US
dc.titleImpact of Food and Drug Administration pediatric antidepressant use warnings on treatment of depression, physician specialty practice patterns, and pharmaceutical stock pricesen_US
dc.typedissertationen_US
dc.contributor.advisorZito, Julie Magno
dc.contributor.advisorMullins, C. Daniel
dc.identifier.ispublishedYesen_US
 Find Full text

This item appears in the following Collection(s)

Show simple item record